<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0704257187
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CYKLOKAPRON INJ 100MG-ML INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TRANEXAMIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        73
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cyklokapron contains tranexamic acid, which belongs to a group of medicines called antihaemorrhagics; antifibrinolytics, amino acids.</p><p>&nbsp;</p><p>Cyklokapron is used in adults and children above 1 year of age for the prevention and treatment of bleeding due to a process that inhibits blood clotting called fibrinolysis.</p><p>Specific indications include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heavy periods in women</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract bleeding after prostate surgery or surgical procedures affecting the urinary tract</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ear, nose or throat surgery</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiovascular, abdominal or gynaecological surgery</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding after you have been treated with another anticoagulant drug.</p><p>&nbsp;</p><p>Tranexamic acid contained in Cyklokapron may also be approved to treat other diseases not mentioned in this leaflet. Ask your doctor, pharmacist or other healthcare professional if you have further questions and always follow their instructions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Cyklokapron:</strong></p><p>If you are allergic to tranexamic acid or any of the other ingredients of this medicine (listed in section 6)</p><p>If you currently have a disease leading to blood clots</p><p>If you have a condition called &ldquo;consumption coagulopathy&rdquo; where the blood in the whole body starts to clot</p><p>If you have kidney problems</p><p>If you have a history of convulsions.</p><p>&nbsp;</p><p>Due to the risk of seizures and brain swelling, Cyklokapron must not be given into the spine, epidurally (around the spinal cord) or into the brain.</p><p>&nbsp;</p><p>If you think any of these apply to you, or if you are in any doubt at all, tell your doctor before taking Cyklokapron.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>This medicine is ONLY to be given to you through a vein either by intravenous infusion (IV) or intravenous injection (IV push). This medicine must not be given into the spine, epidurally (around the spinal cord) or into the brain. Serious harms have been reported when this medicine was given into the spine (intrathecal use). If you notice any pain in your back or legs during, or soon after this medicine is given, tell your doctor or nurse immediately.</p><p>&nbsp;</p><p>Tell your doctor if any of the following apply to you to help him or her decide whether Cyklokapron is suitable for you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; If you have had blood in your urine: Cyklokapron should not be given due to the risk of urinary tract obstruction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;If you are at increased risk of having blood clots. The risk for blood clotting events may be increased in patients using contraceptives containing hormones.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;If you have excessive clotting or bleeding throughout your body (disseminated intravascular coagulation), Cyklokapron may not be suitable for you, except if you have acute severe bleeding and blood tests have shown that the process that inhibits blood clotting (called fibrinolysis) has been activated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not be treated with Cyklokapron if you have a history of convulsions. Your doctor must use the minimal dose possible to avoid convulsions while taking Cyklokapron.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are on long-term treatment with Cyklokapron, attention should be paid to possible disturbances of colour vision and the treatment should be discontinued if necessary.<br />With continuous long-term use of Cyklokapron, regular ophthalmologic examinations (eye examinations including visual acuity, colour vision, fundus, visual field, etc.) are indicated.<br />In the event of pathological ophthalmic changes, particularly with diseases of the retina, your doctor must make a decision in your case after consulting a specialist on the necessity for long-term treatment with Cyklokapron.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Cyklokapron </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>You should specifically tell your doctor if you take or use:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines that help blood to clot, called antifibrinolytic medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that prevent blood clotting, called thrombolytic medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any contraception containing hormones.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Tranexamic acid is excreted in breast milk. Therefore, the use of Cyklokapron during breast-feeding is not recommended.</p><p>&nbsp;</p><p>If you are a woman of child-bearing age, ask your doctor or pharmacist to ensure you are using effective contraception.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>No studies have been performed on the ability to drive and use machines.</p><p><strong>&nbsp;</strong></p><p>You are responsible for assessing whether you are in a condition to drive or perform work that require greater concentration. One of the factors that may affect your ability in this respect is use of medicines, due to their effects and/or side effects. These effects and side effects are described in other sections. Therefore, read all of the information in this leaflet for guidance. Check with your doctor or pharmacist if you are not sure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cyklokapron will be given to you by slow injection or infusion only into a vein and should not be given by any other routes. Your doctor will decide the correct dose for you and how long you should take it.</p><p><strong><s>&nbsp;</s></strong></p><p><strong>Use in children</strong></p><p>For children aged 1 year or older, the dose will be based on the child&rsquo;s weight. The doctor will decide the correct dose for the child and how long he/she should take it.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Use in elderly patients</strong></p><p>No reduction in dosage is necessary unless there is evidence of renal failure.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Use in patients with impaired renal function</strong></p><p>If you suffer from impaired renal function, your dose of tranexamic acid will be reduced according to results from a blood test (serum creatinine level).</p><p>&nbsp;</p><p><strong>Use in patients with impaired hepatic function</strong></p><p>No reduction in dosage is necessary.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Method of administration</strong></p><p>Cyklokapron should only be administrated slowly into a vein.</p><p>Cyklokapron must not be injected into a muscle or into the spine.</p><p><strong>&nbsp;</strong></p><p><strong>If you are given more Cyklokapron than you should</strong></p><p>If you receive more Cyklokapron than the recommended dose, you may experience a transitory drop in blood pressure. Talk to your doctor or pharmacist immediately.</p><p>&nbsp;</p><p>If you have received too much of the medicine or if, for example, a child has taken the medicine by mistake, contact a doctor, hospital or the Swedish Poisons Information Centre (tel. 112) immediately for risk assessment and advice.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>The side</strong><strong> effects reported for Cyklokapron are as follows:</strong></p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal discomfort (nausea, vomiting, diarrhoea)</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on the skin: rash</p><p>&nbsp;</p><p>Has been reported (occurs in an unknown number of users)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; malaise with low blood pressure, with or without loss of consciousness, especially if the injection is given too quickly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on the nervous system: convulsions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on the eyes: visual disturbances including impaired colour vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on the immune system: allergic reactions</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)</strong>&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Store below 25&deg;C.</p><p>&nbsp;</p><p>Shelf life: 3 years.</p><p><br />Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Cyklokapron 100 mg/mL solution for injection/infusion is tranexamic acid.</p><p>The other ingredient is water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cyklokapron 100 mg/mL solution for injection: Type I glass ampoule containing a clear, colourless solution.

Packs  10 ampoules (glass, Type I) of 5 mL in an outer carton, each ampoule containing 500 mg tranexamic acid.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Pfizer Manufacturing Belgium N.V., Puurs, Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong><strong>: </strong></p><p>&nbsp;Pfizer Manufacturing Belgium N.V., Puurs, Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يحتوي سايكلوكابرون على حمض الترانيكساميك الذي ينتمي إلى مجموعة من الأدوية تُسمى الأحماض الأمينية المضادة للنزف، والمضادة لانحلال الفبرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم سايكلوكابرون مع البالغين والأطفال الذين يبلغون من العمر أكثر من عام واحد لمنع وعلاج النزيف الناتج عن عملية تُثبط من تجلط الدم تُسمى انحلال الفبرين.</p><p dir="RTL">تتضمن دواعي الاستعمال الخاصة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دورات الطمث الغزيرة في السيدات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف المعدي المعوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف المسالك البولية بعد جراحة البروستاتا أو الإجراءات الجراحية التي تؤثر على المسالك البولية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جراحات الأذن أو الأنف أو الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جراحات القلب والأوعية الدموية أو جراحات البطن أو جراحات الجهاز التناسلي لدى السيدات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف الذي يتبع خضوعك للعلاج باستخدام دواء مضاد للتخثر آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتم الموافقة أيضًا على حمض الترانيكساميك الموجود في سايكلوكابرون لعلاج أمراض أخرى غير مذكورة في هذه النشرة. إذا كانت لديك أسئلة أخرى، فاسأل الطبيب أو الصيدلي أو أي أخصائي رعاية صحية آخر واتبع تعليماتهم دائمًا.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>موانع استعمال سايكلوكابرون:</strong></p><p dir="RTL">إذا كنت مصابًا بالحساسية تجاه حمض الترانيكساميك أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦)</p><p dir="RTL">إذا كنت مصابًا حاليًا بمرض يؤدي إلى تكون جلطات دموية</p><p dir="RTL">إذا كنت مصابًا بحالة تسمى &quot;الاعتلال الخثري الاستهلاكي&quot; التي تتسبب في بدء تجلط الدم في الجسم بأكمله</p><p dir="RTL">إذا كنت مصابًا بمشكلات في الكلى</p><p dir="RTL">إذا كان لديك تاريخ من الإصابة بالتشنجات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لخطر الإصابة بالنوبات وتورم الدماغ، يجب عدم إعطاء سايكلوكابرون في العمود الفقري، أو في الحيز حول الجافية (حول الحبل الشوكي)، أو داخل الدماغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعتقد أن أيًا من الحالات السابقة تنطبق عليك أو إذا كان لديك أي شك على الإطلاق، فأخبر طبيبك قبل تلقي سايكلوكابرون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال سايكلوكابرون</strong></p><p dir="RTL">يجب إعطاء هذا الدواء من خلال الوريد فقط، إما عن طريق التسريب عبر الوريد (IV) أو الحقن عبر الوريد (دفعة مباشرة عن طريق الوريد). يجب عدم إعطاء هذا الدواء في العمود الفقري، أو في الحيز حول الجافية (حول الحبل الشوكي)، أو داخل الدماغ. تم الإبلاغ عن أضرار خطيرة عند إعطاء هذا الدواء في العمود الفقري (الاستخدام داخل القراب). إذا لاحظت أي ألم في ظهرك أو ساقيك أثناء إعطاء هذا الدواء أو بعده بفترة وجيزة، فأخبر طبيبك أو ممرضك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كانت أي من الحالات التالية تنطبق عليك لمساعدته على اتخاذ القرار بشأن ما إذا كان سايكلوكابرون مناسبًا لك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من قبل من وجود دم في بولك: لا ينبغي إعطاء سايكلوكابرون بسبب خطر الإصابة بانسداد المسالك البولية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت &nbsp;أكثر عرضة لخطر الإصابة بجلطات دموية. قد يزيد خطر الإصابة بأحداث تجلط الدم لدى المريضات اللاتي يستخدمن وسائل منع الحمل &nbsp;التي تحتوي على الهرمونات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بتجلط أو نزيف مفرط في جميع أنحاء جسمك (التخثر المنتشر داخل الأوعية الدموية)، فقد لا يكون سايكلوكابرون ملائمًا لك، إلا في حالة إصابتك بنزيف حاد شديد وأوضحت فحوصات الدم أنه قد تم تنشيط العملية التي تُثبط تجلط الدم (تُسمى انحلال الفبرين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ينبغي عدم تناول سايكلوكابرون، إذا كان لديك تاريخ من التشنجات. يجب أن يستخدم طبيبك أقل جرعة ممكنة لتجنب الإصابة بالتشنجات في أثناء تناول سايكلوكابرون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع لعلاج طويل الأمد باستخدام سايكلوكابرون، ينبغي إيلاء الاهتمام لاضطرابات رؤية الألوان المحتملة وينبغي وقف العلاج إذا لزم الأمر. مع الاستخدام طويل الأمد المستمر لسايكلوكابرون، يوصف الخضوع لفحوصات العين (بما في ذلك فحوصات حدة البصر، رؤية الألوان، قاع العين، مجال الرؤية، إلخ.) بشكل منتظم. في حال حدوث تغيرات مرضية في العين، وخاصةً مع الإصابة بأمراض في الشبكية، يجب أن يتخذ طبيبك قرارًا بعد استشارة أخصائي بشأن ضرورة&nbsp; العلاج طويل الأمد لسايكلوكابرون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتلقى أو تلقيت مؤخرًا أو قد تتلقى أي أدوية أخرى.</p><p dir="RTL">ينبغي أن تخبر طبيبك خاصةً إذا كنت تتناول أو تستخدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى تساعد على تجلط الدم، تُدعى الأدوية المضادة لانحلال الفبرين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تمنع تجلط الدم، تُدعى الأدوية المذيبة للخثرات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي موانع حمل تحتوي على &nbsp;الهرمونات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُفرز حمض الترانيكساميك في لبن الأم. لذلك، لا يوصى باستخدام سايكلوكابرون أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ امرأة في سن الإنجاب، فاسألي طبيبك أو الصيدلي للتأكد من أنكِ تستخدمين وسائل منع الحمل الفعالة.</p><p><strong>&nbsp;</strong></p><p><strong>تأثير سايكلوكابرون على </strong><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لم تُجر أي دراسات لاكتشاف الآثار المتعلقة بالقدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أنت المسؤول عن تقييم ما إذا كنت في حالة تسمح لك بالقيادة أو أداء عمل يتطلب قدرًا أكبر من التركيز. من العوامل التي قد تؤثر في قدرتك في هذا الأمر هو استخدام الأدوية، وذلك بسبب تأثيراتها و/أو آثارها الجانبية. تم وصف هذه التأثيرات والآثار الجانبية في أقسام أخرى. لذا، اقرأ جميع المعلومات الواردة في هذه النشرة للحصول على إرشادات. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا من ذلك.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">سيُعطى سايكلوكابرون إليك بالحقن أو التسريب البطيء في أحد الأوردة فقط وينبغي ألا يُعطى عبر أي مسارات أخرى.<br />سيحدد طبيبك الجرعة الصحيحة بالنسبة لك والمدة التي ينبغي عليك تلقيها خلالها.</p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL"><strong>الاستخدام مع الأطفال</strong></p><p dir="RTL">بالنسبة إلى الأطفال من عمر عام واحد أو أكبر، فسيتم تحديد الجرعة وفقًا لوزن الطفل. سيحدد الطبيب الجرعة الصحيحة للطفل والمدة التي ينبغي أن يتلقاها خلالها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع المرضى المسنين</strong></p><p dir="RTL">لا يلزم تقليل الجرعة ما لم يكن هناك دليل على الإصابة بفشل كلوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع المرضى الذين يعانون اختلال وظائف الكلى</strong></p><p dir="RTL">إذا كنت تعاني اختلالًا في وظائف الكلى، فسيتم تقليل جرعتك من حمض الترانيكساميك وفقًا لنتائج فحص الدم (مستوى كرياتينين المصل).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع المرضى الذين يعانون اختلال وظائف الكبد</strong></p><p dir="RTL">لا يلزم تقليل الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستعمال</strong></p><p dir="RTL">ينبغي استعمال سايكلوكابرون فقط بالحقن البطيء في أحد الأوردة.</p><p dir="RTL">يجب ألا يُحقن سايكلوكابرون في العضل أو في العمود الفقري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من سايكلوكابرون</strong></p><p dir="RTL">إذا تم إعطاؤك جرعة من سايكلوكابرون أكبر من الجرعة الموصى بها فقد تتعرض لانخفاض مؤقت في ضغط الدم. تحدث مع طبيبك أو الصيدلي على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت كمية زائدة من الدواء أو إذا تناول طفل الدواء عن طريق الخطأ، على سبيل المثال، فاتصل فورًا بالطبيب أو المستشفى لتقييم المخاطر وتقديم المشورة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">سيُعطى سايكلوكابرون إليك بالحقن أو التسريب البطيء في أحد الأوردة فقط وينبغي ألا يُعطى عبر أي مسارات أخرى.<br />سيحدد طبيبك الجرعة الصحيحة بالنسبة لك والمدة التي ينبغي عليك تلقيها خلالها.</p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL"><strong>الاستخدام مع الأطفال</strong></p><p dir="RTL">بالنسبة إلى الأطفال من عمر عام واحد أو أكبر، فسيتم تحديد الجرعة وفقًا لوزن الطفل. سيحدد الطبيب الجرعة الصحيحة للطفل والمدة التي ينبغي أن يتلقاها خلالها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع المرضى المسنين</strong></p><p dir="RTL">لا يلزم تقليل الجرعة ما لم يكن هناك دليل على الإصابة بفشل كلوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع المرضى الذين يعانون اختلال وظائف الكلى</strong></p><p dir="RTL">إذا كنت تعاني اختلالًا في وظائف الكلى، فسيتم تقليل جرعتك من حمض الترانيكساميك وفقًا لنتائج فحص الدم (مستوى كرياتينين المصل).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام مع المرضى الذين يعانون اختلال وظائف الكبد</strong></p><p dir="RTL">لا يلزم تقليل الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستعمال</strong></p><p dir="RTL">ينبغي استعمال سايكلوكابرون فقط بالحقن البطيء في أحد الأوردة.</p><p dir="RTL">يجب ألا يُحقن سايكلوكابرون في العضل أو في العمود الفقري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من سايكلوكابرون</strong></p><p dir="RTL">إذا تم إعطاؤك جرعة من سايكلوكابرون أكبر من الجرعة الموصى بها فقد تتعرض لانخفاض مؤقت في ضغط الدم. تحدث مع طبيبك أو الصيدلي على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت كمية زائدة من الدواء أو إذا تناول طفل الدواء عن طريق الخطأ، على سبيل المثال، فاتصل فورًا بالطبيب أو المستشفى لتقييم المخاطر وتقديم المشورة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ عند درجة حرارة اقل من ٢٥ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">صلاحية المستحضر ٣ سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد مُضي تاريخ الصلاحية المدون على العبوة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم بتجميده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المادة الفعالة في محلول سايكلوكابرون ١٠٠ ملجم/مل المخصص للحقن/التسريب هي حمض الترانيكساميك</p><p dir="RTL">المكون الآخر هو ماء للحقن.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">محلول سايكلوكابرون ١٠٠ ملجم/مل المخصص للحقن: أمبولة زجاجية من النوع الأول تحتوي على محلول صافٍ عديم اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عبوات تحتوي على ١٠ أمبولات (زجاج من النوع الأول) سعة ٥ مل في عبوة كرتونية خارجية، وتحتوي كل أمبولة على ٥٠٠ ملجم من حمض الترانيكساميك.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق:</strong></p><p dir="RTL"><strong>&nbsp;</strong>Pfizer Manufacturing Belgium N.V., Puurs, Belgium</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة: </strong></p><p dir="RTL">Pfizer Manufacturing Belgium N.V., Puurs, Belgium</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو/أيار ۲۰۲٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cyklokapron100 mg/mL solution for injection/infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 1 mL contains 100 mg tranexamic acid.

Each 5 mL ampoule contains 500 mg tranexamic acid.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection/infusion.

Clear, colourless solution with pH of 6.5 8.0.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tranexamic acid is indicated in adults and children from one year in prevention and treatment of haemorrhages due to general or local fibrinolysis.</p><p>Specific indications include:</p><p>-Haemorrhage caused by general or local fibrinolysis such as:</p><p>-Menorrhagia and metrorrhagia,</p><p>-Gastrointestinal bleeding,</p><p>-Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract,</p><p>-Ear Nose Throat surgery (adenoidectomy, tonsillectomy, dental extractions),</p><p>-Gynaecological surgery or disorders of obstetric origin,</p><p>-Thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery,</p><p>-Management of haemorrhage due to the administration of a fibrinolytic agent.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em>Adults</em></p><p>Unless otherwise prescribed, the following doses are recommended:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Standard treatment of local fibrinolysis:</p><p>0.5&nbsp;g (1 ampoule of 5&nbsp;mL) to 1&nbsp;g (1 ampoule of 10&nbsp;mL or 2 ampoules of 5&nbsp;mL) tranexamic acid by slow intravenous injection or infusion (= 1&nbsp;mL/minute) two to three times daily</p><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Standard treatment of general fibrinolysis:</p><p>1 g (1 ampoule of 10&nbsp;mL or 2 ampoules of 5&nbsp;mL) tranexamic acid by slow intravenous injection or infusion (=&nbsp;1&nbsp;mL/minute) every 6 to 8&nbsp;hours, equivalent to 15&nbsp;mg/kg body weight (BW)</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>In renal insufficiency leading to a risk of accumulation, the use of tranexamic acid is contra-indicated in patient with severe renal impairment (see section 4.3). For patients with mild to moderate renal impairment, the dosage of tranexamic acid should be reduced according to the serum creatinine level:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Serum creatinine</p><p>micromol/L</p></td><td style="vertical-align:top"><p>mg/10&nbsp;mL</p></td><td style="vertical-align:top"><p>Dose IV</p></td><td style="vertical-align:top"><p>Administration</p></td></tr><tr><td style="vertical-align:top"><p>120 to 249</p></td><td style="vertical-align:top"><p>1.35 to 2.82</p></td><td style="vertical-align:top"><p>10&nbsp;mg/kg BW</p></td><td style="vertical-align:top"><p>Every 12&nbsp;hours</p></td></tr><tr><td style="vertical-align:top"><p>250 to 500</p></td><td style="vertical-align:top"><p>2.82 to 5.65</p></td><td style="vertical-align:top"><p>10&nbsp;mg/kg BW</p></td><td style="vertical-align:top"><p>Every 24&nbsp;hours</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 500</p></td><td style="vertical-align:top"><p>&gt; 5.65</p></td><td style="vertical-align:top"><p>5&nbsp;mg/kg BW</p></td><td style="vertical-align:top"><p>Every 24&nbsp;hours</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>No dose adjustment is required in patient with hepatic impairment.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In children from 1 year, for current approved indications as described in section 4.1, the dosage is in the region of 20&nbsp;mg/kg/day. However, data on efficacy, posology and safety for these indications are limited. The efficacy, posology and safety of tranexamic acid in children undergoing cardiac surgery have not been fully established. Currently available data are limited and are described in section 5.1.</p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>No reduction in dosage is necessary unless there is evidence of renal failure.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Method of administration </u></p><p><strong>&nbsp;</strong></p><p>The administration is strictly limited to slow intravenous injection or infusion (see section 6.6) of maximum 1 mL per minute.</p><p>&nbsp;</p><p><strong>TRANEXAMIC ACID SHOULD ONLY BE ADMINISTERED INTRAVENOUSLY </strong><strong><em>and should not be administered intrathecally or epidural </em></strong>(see sections 4.3 and 4.4)<strong>.</strong></p><p><strong>&nbsp;</strong></p><p>IN ORDER TO REDUCE THE RISK OF FATAL MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION OF TRANEXAMIC ACID, IT IS STRONGLY RECOMMENDED TO LABEL THE SYRINGES CONTAINING TRANEXAMIC ACID (see sections 4.3, 4.4 and 6.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Acute venous or arterial thrombosis (see section 4.4).
Fibrinolytic conditions following consumption coagulopathy except in those with predominant activation of the fibrinolytic system with acute severe bleeding (see section 4.4).
Severe renal impairment (risk of accumulation).
History of convulsions.
Intrathecal, epidural and intraventricular injection and intracerebral application (risk of cerebral oedema, convulsions and death).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The indications and method of administration indicated above should be followed strictly:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intravenous injections or infusions should be given very slowly (max. 1 mL per minute)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tranexamic acid must not be administered by the intramuscular route</p><p>&nbsp;</p><p><u>Risk of medication errors due to incorrect route of administration</u></p><p><u>&nbsp;</u></p><p>Cyklokapron is only for intravenous use. Intrathecal, epidural, intraventricular and intracerebral use of Cyklokapron is contraindicated (see section 4.3). Serious adverse reactions including fatal events have been reported when tranexamic acid was inadvertently administered intrathecally. These events have included severe back, gluteal and lower limb pain, myoclonus and generalised seizures and cardiac arrhythmias.</p><p>&nbsp;</p><p>Care should be exercised to ensure the correct route of administration of Cyklokapron. Healthcare professionals should be aware of the potential for confusion of Cyklokapron with other injectables which could result in inadvertent intrathecal administration of Cyklokapron. This includes in particular intrathecally administered injectables that may be used during the same procedure as tranexamic acid.</p><p>&nbsp;</p><p>Syringes containing Cyklokapron should be clearly labelled with the intravenous route of administration.</p><p>&nbsp;</p><p><u>Convulsions</u></p><p><u>&nbsp;</u></p><p>Cases of convulsions have been reported in association with tranexamic acid treatment. In coronary artery bypass graft (CABG) surgery, most of these cases were reported following intravenous (IV.) injection of tranexamic acid in high doses. With the use of the recommended lower doses of tranexamic acid, the incidence of post-operative seizures was the same as that in untreated patients.</p><p>&nbsp;</p><p><u>Visual disturbances</u></p><p><u>&nbsp;</u></p><p>Attention should be paid to possible visual disturbances including visual impairment, vision blurred, impaired colour vision and if necessary the treatment should be discontinued. With continuous long‑term use of tranexamic acid, regular ophthalmologic examinations (eye examinations including visual acuity, colour vision, fundus, visual field etc.) are indicated. With pathological ophthalmic changes, particularly with diseases of the retina, the physician must decide after consulting a specialist on the necessity for the long-term use of tranexamic acid in each individual case.</p><p>&nbsp;</p><p><u>Haematuria</u></p><p><u>&nbsp;</u></p><p>In case of haematuria from the upper urinary tract, there is a risk for urinary obstruction at the lower levels of the tract.</p><p>&nbsp;</p><p>If left untreated, urinary obstruction may lead to serious consequences such as renal insufficiency, urinary tract infection, hydronephrosis, and anuria. Therefore, close monitoring is recommended for patients with haematuria or risk of haematuria from the upper urinary tract.</p><p>&nbsp;</p><p><u>Thromboembolic events</u></p><p><u>&nbsp;</u></p><p>Before use of tranexamic acid, risk factors of thromboembolic disease should be considered. In patients with a history of thromboembolic diseases or in those with increased incidence of thromboembolic events in their family history (patients with a high risk of thrombophilia), tranexamic acid should only be administered if there is a strong medical indication after consulting a physician experienced in haemostaseology and under strict medical supervision (see section 4.3).</p><p>&nbsp;</p><p>Tranexamic acid should be administered with care in patients using hormonal contraception because of the increased risk of thrombosis (see section 4.5).</p><p>&nbsp;</p><p><u>Disseminated intravascular coagulation</u></p><p><u>&nbsp;</u></p><p>Patients with disseminated intravascular coagulation (DIC) should in most cases not be treated with tranexamic acid (see section 4.3). If tranexamic acid is given it must be restricted to those in whom there is predominant activation of the fibrinolytic system with acute severe bleeding. Characteristically, the haematological profile approximates to the following: reduced euglobulin clot lysis time; prolonged prothrombin time; reduced plasma levels of fibrinogen, factors V and VIII, plasminogen fibrinolysin and alpha-2 macroglobulin; normal plasma levels of P and P complex; i.e. factors II (prothrombin), VIII and X; increased plasma levels of fibrinogen degradation products; a normal platelet count. The foregoing presumes that the underlying disease state does not of itself modify the various elements in this profile. In such acute cases a single dose of 1 g tranexamic acid is frequently sufficient to control bleeding. Administration of tranexamic acid in DIC should be considered only when appropriate haematological laboratory facilities and expertise are available.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. Simultaneous treatment with anticoagulants must take place under the strict supervision of a physician experienced in this field. Medicinal products that act on haemostasis should be given with caution to patients treated with tranexamic acid. There is a risk of increased thrombus-formation potential during concomitant use with hormonal contraception. Alternatively, the antifibrinolytic action of the drug may be antagonised with thrombolytic drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of childbearing potential have to use effective contraception during treatment (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or foetal outcomes. There are cases of foetal structural abnormalities that resulted in death of the newborn following administration of tranexamic acid to the mother during conception or the first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>Tranexamic acid passes through the placenta. The concentration in cord blood after an intravenous injection of 10 mg/kg to pregnant women is about 30 mg/l, as high as in the maternal blood.</p><p>&nbsp;</p><p>There were 13 clinical studies that described foetal and/or neonatal functional issues such as low Apgar score, neonatal sepsis, cephalohematoma and 9 clinical studies that discussed alterations to growth including low birth weight and preterm birth at 22‑36&nbsp;weeks of gestation in foetuses and infants exposed to tranexamic acid <em>in‑utero</em>.</p><p>&nbsp;</p><p>For decisions regarding the use of tranexamic acid during pregnancy, the potential risk of tranexamic acid administration on the foetus should always be considered along with the mother&rsquo;s clinical need for tranexamic acid; an accurate risk-benefit evaluation should drive the treating physician&rsquo;s decision.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>Published literature reports the presence of tranexamic acid in human milk. There are limited data on the effects of tranexamic acid on the breast-fed child or the effects on milk production. The developmental and health benefits of breast-feeding should be considered along with the mother&rsquo;s clinical need for tranexamic acid and any potential adverse effects on the breast-fed child from tranexamic acid or from the underlying maternal condition.</p><p>&nbsp;</p><p>Due to limited data, no final assessment can be established on the use of tranexamic acid during breast‑feeding.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no clinical data on the effects of tranexamic acid on fertility. In animal studies, tranexamic acid did not affect male or female fertility at clinically relevant doses (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been performed on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ADRs reported from clinical studies and post-marketing experience are listed below according to system organ class.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions </u></p><p>&nbsp;</p><p>Adverse reactions reported are presented in table below. Adverse reactions are listed according to MedDRA primary system organ class. Within each system organ class, adverse reactions are ranked by frequency. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. The frequencies are defined as follows: Very common (&ge;1/10), Common (&ge;1/100, &lt;1/10), Uncommon (&ge;1/1&nbsp;000, &lt;1/100), Frequency not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge;1/100 to &lt;1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge;1/1,000 to</strong></p><p><strong>&lt;1/100</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known </strong></p><p><strong>(cannot be estimated from the available data)</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>- Hypersensitivity reactions including anaphylaxis</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>- Convulsions particularly in case of misuse (see sections 4.3 and 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>- Visual disturbances including impaired colour vision</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>- Malaise with hypotension, with or without loss of consciousness (generally following a too fast intravenous injection, exceptionally after oral administration)</p><p>- Arterial or venous thrombosis at any sites</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>- Diarrhoea</p><p>- Vomiting</p><p>- Nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>- Dermatitis allergic</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)&nbsp; </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported.</p><p>&nbsp;</p><p>Signs and symptoms may include dizziness, headache, hypotension, and convulsions. It has been shown that convulsions tend to occur at higher frequency with increasing dose.</p><p>Management of overdose should be supportive.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antihaemorrhagics, Antifibrinolytics, Amino acids;<br />ATC code: B02AA02</p><p>&nbsp;</p><p>Tranexamic acid exerts an anti haemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.</p><p>&nbsp;</p><p>A complex involving tranexamic acid, plasminogen is constituted; the tranexamic acid being linked to plasminogen when transformed into plasmin.</p><p>&nbsp;</p><p>The activity of the tranexamic acid-plasmin complex on the activity on fibrin is lower than the activity of free plasmin alone.</p><p>&nbsp;</p><p><em>In vitro </em>studies showed that high tranexamic dosages decreased the activity of complement.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em>In children over one year old</em></p><p>Literature review identified 12 efficacy studies in paediatric cardiac surgery which have included 1073 children, 631 having received tranexamic acid. Most of them were controlled versus placebo. Studied population was heterogenic in terms of age, surgery types, dosing schedules. Study results with tranexamic acid suggest reduced blood loss and reduced blood product requirements in paediatric cardiac surgery under cardiopulmonary bypass (CPB) where there is a high risk of haemorrhage, especially in cyanotic patients or patients undergoing repeat surgery. The most adapted dosing schedule appeared to be:</p><p>-&nbsp;&nbsp; First bolus of 10&nbsp;mg/kg after induction of anaesthesia and prior to skin incision.</p><p>-&nbsp;&nbsp; Continuous infusion of 10&nbsp;mg/kg/h or injection into the CPB pump prime at a dose adapted on the CPB procedure, either according to a patient weight with a dose of 10&nbsp;mg/kg dose, either according to CPB pump prime volume, last injection of 10&nbsp;mg/kg at the end of CPB.</p><p>&nbsp;</p><p>While studied in very few patients, the limited data suggest that continuous infusion is preferable, since it would maintain therapeutic plasma concentration throughout surgery.</p><p>&nbsp;</p><p>No specific dose-effect study or PK study has been conducted in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Peak plasma concentrations of tranexamic acid are obtained rapidly after a short intravenous infusion after which plasma concentrations decline in a multi-exponential manner.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen. Tranexamic acid does not bind to serum albumin. The initial volume of distribution is about 9 to 12 litres.</p><p>Tranexamic acid passes through the placenta. Following administration of an intravenous injection of 10&nbsp;mg/kg to 12 pregnant women, the concentration of tranexamic acid in serum ranged 10‑53&nbsp;micrograms/mL while that in cord blood ranged 4-31&nbsp;microgram/mL. Tranexamic acid diffuses rapidly into joint fluid and the synovial membrane. Following administration of an intravenous injection of 10&nbsp;mg/kg to 17 patients undergoing knee surgery, concentrations in the joint fluids were similar to those seen in corresponding serum samples. The concentration of tranexamic acid in a number of other tissues is a fraction of that observed in the blood (breast milk, one hundredth; cerebrospinal fluid, one tenth; aqueous humor, one tenth). Tranexamic acid has been detected in semen where it inhibits fibrinolytic activity but does not influence sperm migration.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>It is excreted mainly in the urine as unchanged drug. Urinary excretion via glomerular filtration is the main route of elimination. Renal clearance is equal to plasma clearance (110 to 116&nbsp;mL/min). Excretion of tranexamic acid is about 90% within the first 24&nbsp;hours after intravenous administration of 10&nbsp;mg/kg body weight. Elimination half-life of tranexamic acid is approximately 3&nbsp;hours</p><p>&nbsp;</p><p><u>Other special populations</u></p><p><u>&nbsp;</u></p><p>Plasma concentrations increase in patients with renal failure.</p><p>No specific pharmacokinetic study has been conducted in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis and mutagenesis</u></p><p>&nbsp;</p><p>No evidence of carcinogenicity or mutagenicity was observed in conventional studies with tranexamic acid.</p><p>&nbsp;</p><p><u>Reproductive toxicity</u></p><p>&nbsp;</p><p>In reproductive toxicity studies (fertility and early embryonic development studies, embryo-foetal development studies, and pre-and postnatal studies), tranexamic acid had no adverse effect on reproductive parameters of mice, rats and rabbits at clinically relevant doses.</p><p>&nbsp;</p><p><u>General toxicology</u></p><p>&nbsp;</p><p>Retinal toxicity has been observed in nonclinical studies with tranexamic acid. The observed toxicity was characterised by retinal atrophy commencing with changes to the retinal pigmented epithelium and progressing to retinal detachment in cats. The toxicity appeared to be dose-related, and changes were partially reversible at lower doses. Effects (some fully reversible) were seen in cats at clinically relevant doses, effects in dogs were only observed at multiples of the clinical dose. Studies suggest that the underlying mechanism may be related to a transient retinal ischemia at higher dose exposures, linked to the known sympathomimetic effect of high plasma levels of tranexamic acid. The clinical relevance of these findings is unknown.</p><p><strong>&nbsp;</strong></p><p>Epileptogenic activity has been observed in animals with intrathecal use of tranexamic acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should not be mixed with blood for transfusion or with solutions containing penicillin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
Do not use Cyklokapron after the expiry date which is stated on the Ampoule label after EXP:. The expiry date refers to the last day of that month
 
Store below 25°C.

After first opening: the solution for injection/infusion is for single use only. Unused solution must be discarded.

Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not freeze.</p><p><strong>&nbsp;</strong></p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packs with 10 (Type I glass) 5&nbsp;mL ampoules in an outer carton, each ampoule containing 500&nbsp;mg tranexamic acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Keep out of the sight and reach of children.</strong></p><p>&nbsp;</p><p>Healthcare professionals are strongly advised to label the Cyklokapron syringes during the withdrawal of the product from the ampoule for clear identification and proper route of administration, to help prevent inadvertent medication errors during administration to the patient.</p><p>&nbsp;</p><p>Cyklokapron may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions and dextran solutions. Heparin may be added to Cyklokapron.</p><p>&nbsp;</p><p>Cyklokapron is for single use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Manufacturing Belgium N.V., Puurs, Belgium


 
 
MANUFACTURER 
 Pfizer Manufacturing Belgium N.V., Puurs, Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>